Astellas Pharma Inc: Urinary Incontinence trials

The registry lists 21 Urinary Incontinence studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 3Phase 2 3Phase 3 11Phase 4 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)CompletedNCT02216214Phase 4Results posted
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderCompletedNCT02045862Phase 3Results posted
• This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive BladderCompletedNCT01972841Phase 3Results posted
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)CompletedNCT01908829Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.CompletedNCT01638000Phase 3Results posted
• A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical ProstatectomyCompletedNCT01371994Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderCompletedNCT01340027Phase 2Results posted
• A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00912964Phase 3Results posted
• Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00689104Phase 3Results posted
• Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00688688Phase 3Results posted
• A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00662909Phase 3Results posted
• EC905 Pharmacokinetic Profile StudyCompletedNCT02634489Phase 1
• Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01604928Phase 2
• A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy VolunteersCompletedNCT01334905Phase 1
• A Study of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01043666Phase 3
• A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive BladderCompletedNCT00966004Phase 3
• A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly VolunteersCompletedNCT00965926Phase 1
• A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder PatientsCompletedNCT00368706Phase 3
• A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)CompletedNCT00337558Phase 4
• A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)CompletedNCT00337090Phase 2
• A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.CompletedNCT00333112Phase 4